Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Podofilox. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 6/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 6/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.55 |
| ▸ | TUBB4A | P04350 | 4/20 | 0.55 |
| ▸ | TUBB | P07437 | 4/20 | 0.55 |
| ▸ | TUBA3C | P0DPH7 | 4/20 | 0.55 |
| ▸ | TUBA1B | P68363 | 4/20 | 0.55 |
| ▸ | TUBA4A | P68366 | 4/20 | 0.55 |
| ▸ | TUBB4B | P68371 | 4/20 | 0.55 |
| ▸ | TUBB3 | Q13509 | 4/20 | 0.55 |
| ▸ | TUBB2A | Q13885 | 4/20 | 0.55 |
| ▸ | TUBB8 | Q3ZCM7 | 4/20 | 0.55 |
| ▸ | TUBA3E | Q6PEY2 | 4/20 | 0.55 |
| ▸ | TUBA1A | Q71U36 | 4/20 | 0.55 |
| ▸ | TUBA1C | Q9BQE3 | 4/20 | 0.55 |
| ▸ | TUBB6 | Q9BUF5 | 4/20 | 0.55 |
| ▸ | TUBB2B | Q9BVA1 | 4/20 | 0.55 |
| ▸ | TUBB1 | Q9H4B7 | 4/20 | 0.55 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Podofilox SCHEMBL9205728 | 0.75 | LMNA (0.98) | LMNACYP3A4SMN1; SMN2TUBB4ATUBB | |
| Axl-1717 SCHEMBL1287609 | 0.75 | LMNA (0.98) | LMNACYP3A4SMN1; SMN2TUBB4ATUBB | |
| Podofilox SCHEMBL9205950 | 0.75 | LMNA (0.98) | LMNACYP3A4SMN1; SMN2TUBB4ATUBB | |
| Podofilox SCHEMBL42243 | 0.74 | LMNA (1.00) | LMNACYP3A4SMN1; SMN2TUBB4ATUBB | |
| Podofilox SCHEMBL13661743 | 0.74 | LMNA (1.00) | LMNACYP3A4SMN1; SMN2TUBB4ATUBB | |
| Podofilox SCHEMBL24049951 | 0.74 | LMNA (1.00) | LMNACYP3A4SMN1; SMN2TUBB4ATUBB | |
| Podofilox SCHEMBL13663652 | 0.74 | LMNA (1.00) | LMNACYP3A4SMN1; SMN2TUBB4ATUBB | |
| Podofilox SCHEMBL20807187 | 0.74 | LMNA (1.00) | LMNACYP3A4SMN1; SMN2TUBB4ATUBB | |
| Podofilox SCHEMBL10046308 | 0.74 | LMNA (1.00) | LMNACYP3A4SMN1; SMN2TUBB4ATUBB | |
| Epipodophyllotoxin SCHEMBL5792464 | 0.74 | LMNA (1.00) | LMNACYP3A4SMN1; SMN2TUBB4ATUBB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10772878-B2 | Demethylpenclomedine analogs and their use as anti-cancer agents | DEKK-TEC, INC. (US) | 2020-09-15 | — | — | US | claimed |
| US-20180117022-A1 | DEMETHYLPENCLOMEDINE ANALOGS AND THEIR USE AS ANTI-CANCER AGENTS | DEKK-TEC, INC. (US) | 2018-05-03 | — | — | US | claimed |
| US-9884051-B2 | Demethylpenclomedine analogs and their use as anti-cancer agents | DEKK-TEC, INC. (US) | 2018-02-06 | — | — | US | claimed |
| EP-1981850-B1 | DEMETHYLPENCLOMEDINE ANALOGS AND THEIR USE AS ANTICANCER AGENTS | DEKK-TEC INC (US) | 2017-03-22 | — | — | EP | claimed |
| US-20160354354-A1 | DEMETHYLPENCLOMEDINE ANALOGS AND THEIR USE AS ANTI-CANCER AGENTS | DEKK-TEC, INC. (US) | 2016-12-08 | — | — | US | claimed |
| US-8795659-B2 | Salts of isophosphoramide mustard and analogs thereof as anti-tumor agents | DEKK-TEC, INC. (US) | 2014-08-05 | — | — | US | claimed |
| US-20130149296-A1 | Salts of Isophosphoramide Mustard and Analogs Thereof As Anti-Tumor Agents | DEKK-TEC, INC. | 2013-06-13 | — | — | US | claimed |
| EP-2240175-B1 | COMPOUNDS WITH MDR1-INVERSE ACTIVITY | US GOV HEALTH & HUMAN SERV (US) | 2013-01-02 | — | — | EP | claimed |
| US-8232262-B2 | Hyperproliferative disorders; lyophilisates; shelf life; pharmacokinetics | DEKK-TEC, INC. (US) | 2012-07-31 | — | — | US | claimed |
| US-20120177634-A1 | DEMETHYLPENCLOMEDINE ANALOGS AND THEIR USE AS ANTI-CANCER AGENTS | DEKK-TEC, INC. | 2012-07-12 | — | — | US | claimed |
| US-20090004118-A1 | Multifunctional Nanoparticle Conjugates And Their Use | GEORGIA TECH RESEARCH CORPORATION | 2009-01-01 | — | — | US | claimed |
| US-20080267945-A1 | Salts of Isophosphoramide Mustard and Analogs Thereof as Anti-Tumor Agents | DEKK-TEC, INC (US) | 2008-10-30 | — | — | US | claimed |
| EP-1981850-A2 | DEMETHYLPENCLOMEDINE ANALOGS AND THEIR USE AS ANTICANCER AGENTS | Dekk-Tec, Inc. (US) | 2008-10-22 | — | — | EP | claimed |
| WO-2008098138-A1 | SYNTHETIC MACROCYCLIC COMPOUNDS FOR TREATING CANCER | THE GOVERNMENT OF THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2008-08-14 | — | — | WO | claimed |
| EP-1812864-A2 | MULTIFUNCTIONAL NANOPARTICLES CONJUGATES AND THEIR USE | EMORY UNIVERSITY (US) | 2007-08-01 | — | — | EP | claimed |
| EP-1805192-A2 | SALTS OF ISOPHOSPHORAMIDE MUSTARD AND ANALOGS THEREOF AS ANTI-TUMOR AGENTS | Dekk-Tec, Inc. (US) | 2007-07-11 | — | — | EP | claimed |
| WO-2007070568-A2 | DEMETHYLPENCLOMEDINE ANALOGS AND THEIR USE AS ANTICANCER AGENTS | DEKK-TEC, INC. (US) | 2007-06-21 | — | — | WO | claimed |
| WO-2006047575-A2 | SALTS OF ISOPHOSPHORAMIDE MUSTARD AND ANALOGS THEREOF AS ANTI-TUMOR AGENTS | DEKK-TEC INC. (US) | 2006-05-04 | — | — | WO | claimed |
| US-20060089333-A1 | Salts of isophosphoramide mustard and analogs thereof as anti-tumor agents | DEKK-TEC INC. (US) | 2006-04-27 | — | — | US | claimed |
| WO-2006042146-A2 | MULTIFUNCTIONAL NANOPARTICLES CONJUGATES AND THEIR USE | EMORY UNIVERSITY (US) | 2006-04-20 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090004118-A1 | Multifunctional Nanoparticle Conjugates And Their Use | CD47, MSN, TSG101 | LMNA 1922/4885CYP3A4 4786/4885SMN1; SMN2 370/4885 |
| US-20160354354-A1 | DEMETHYLPENCLOMEDINE ANALOGS AND THEIR USE AS ANTI-CANCER AGENTS | MCL1, DNMT1, MYC | LMNA 1636/4885CYP3A4 3548/4885SMN1; SMN2 1513/4885 |
| US-10772878-B2 | Demethylpenclomedine analogs and their use as anti-cancer agents | MCL1, DNMT1, MYC | LMNA 1636/4885CYP3A4 3548/4885SMN1; SMN2 1513/4885 |
| US-20080267945-A1 | Salts of Isophosphoramide Mustard and Analogs Thereof as Anti-Tumor Agents | ATIC, HASPIN, TP53 | LMNA 2722/4885CYP3A4 3956/4885SMN1; SMN2 2854/4885 |
| US-20060089333-A1 | Salts of isophosphoramide mustard and analogs thereof as anti-tumor agents | ATIC, HASPIN, TP53 | LMNA 2722/4885CYP3A4 3956/4885SMN1; SMN2 2854/4885 |
| US-20130149296-A1 | Salts of Isophosphoramide Mustard and Analogs Thereof As Anti-Tumor Agents | HASPIN, ATIC, WEE1 | LMNA 2719/4885CYP3A4 4163/4885SMN1; SMN2 2873/4885 |
| US-20120177634-A1 | DEMETHYLPENCLOMEDINE ANALOGS AND THEIR USE AS ANTI-CANCER AGENTS | MCL1, DNMT1, MYC | LMNA 1636/4885CYP3A4 3548/4885SMN1; SMN2 1513/4885 |
| US-20180117022-A1 | DEMETHYLPENCLOMEDINE ANALOGS AND THEIR USE AS ANTI-CANCER AGENTS | MCL1, DNMT1, MYC | LMNA 1636/4885CYP3A4 3548/4885SMN1; SMN2 1513/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.